Domov › Trojno negativni rak dojke › Massachusetts › Boston
Klinične študije za Trojno negativni rak dojke v Boston, MA
26 študij za Trojno negativni rak dojke išče udeležence na lokacijah v Boston in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Vključevanje udeležencevFaza 1
- Massachusetts General Hospital, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Vključevanje udeležencevFaza 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- Dana Farber Cancer Institute, Boston
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Vključevanje udeležencevFaza 1
- Dana-Farber Cancer Institute, Boston
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Vključevanje udeležencevFaza 3
- Massachusetts General Hospital Cancer Center ( Site 0091), Boston
- Dana Farber Cancer Institute ( Site 0090), Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Vključevanje udeležencevFaza 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer
Vključevanje udeležencev
- Massachusetts General Hospital, Boston
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Vključevanje udeležencevFaza 3
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Vključevanje udeležencevFaza 1
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Vključevanje udeležencevFaza 1
- Dana-Farber Cancer Institute, Boston
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Vključevanje udeležencevFaza 2/3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Vključevanje udeležencevFaza 2
- Dana-Farber Cancer Institute, Boston
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Vključevanje udeležencevFaza 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Vključevanje udeležencevFaza 1
- Massachusetts General Hospital, Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Vključevanje udeležencevFaza 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Sacituzumab Govitecan In TNBC
Vključevanje udeležencevFaza 2
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Vključevanje udeležencevFaza 1
- Dana-Farber Cancer Institute, Boston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Vključevanje udeležencevFaza 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4175408 in Participants With Advanced Cancer
Vključevanje udeležencevFaza 1
- Massachusetts General Hospital, Boston
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Vključevanje udeležencevFaza 2
- Dana-Farber Cancer Institute, Boston
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Vključevanje udeležencevFaza 2
- Dana Farber Cancer Institute, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Dana Farber Cancer Institute, Boston
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Vključevanje udeležencevFaza 1
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Vključevanje udeležencevFaza 1/2
- Massachusetts General Hospital, Boston
Študije za Trojno negativni rak dojke v drugih mestih
- Houston, TX42 študij
- New York City, NY31 študij
- Nashville, TN28 študij
- Los Angeles, CA27 študij
- San Antonio, TX23 študij
- St. Louis, MO21 študij
- Arlington, VA20 študij
- Atlanta, GA20 študij
- Dallas, TX18 študij
- Chicago, IL16 študij
- Columbus, OH16 študij
- Grand Rapids, MI15 študij
Druge študije v Boston
- Rak dojke112 študij
- Nemalicelični pljučni rak90 študij
- Rak (vse vrste)85 študij
- Metastatski rak63 študij
- Kolorektalni rak63 študij
- Rak pljuč62 študij
- Rak jajčnikov61 študij
- Rak prostate59 študij
- Depresija52 študij
- Rak endometrija50 študij
- Srčno popuščanje44 študij
- Akutna mieločna levkemija44 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.